OncoMatch/Clinical Trials/NCT06086704
Study of 18F-FFNP Breast PET/MRI
Is NCT06086704 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including 18F-fluorofuranylnorprogesterone and Positron Emissions Tomography / Magnetic Resonance Imaging for breast cancer.
Treatment: 18F-fluorofuranylnorprogesterone · Positron Emissions Tomography / Magnetic Resonance Imaging · Anastrozole · FDA-approved gadolinium-based intravenous contrast agent — This clinical trial will investigate an estrogen-regulated parameter as an early measure of endocrine therapy response: progesterone receptor (PR) protein with a progestin-based radioligand, 18F-fluorofuranylnorprogesterone (18F-FFNP). The overall purpose of this research is to test the efficacy of 18F-FFNP PET/MRI for predicting response to presurgical endocrine therapy and to determine the quantitative reliability of 18F-FFNP breast PET/MRI in patients with newly diagnosed PR+ primary breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: PR (PGR) expression (positive)
Biopsy-proven PR-positive invasive breast cancer
Excluded: HER2 (ERBB2) overexpression
HER2-positive breast cancer, as defined by immunohistochemical staining 3+ OR positive by in situ hybridization
Demographics
Prior therapy
Cannot have received: neoadjuvant chemotherapy
Patients who have completed neoadjuvant chemotherapy, endocrine therapy, targeted therapy, surgical resection, or radiation for the current biopsy-proven malignancy
Cannot have received: neoadjuvant endocrine therapy
Patients who have completed neoadjuvant chemotherapy, endocrine therapy, targeted therapy, surgical resection, or radiation for the current biopsy-proven malignancy
Cannot have received: neoadjuvant targeted therapy
Patients who have completed neoadjuvant chemotherapy, endocrine therapy, targeted therapy, surgical resection, or radiation for the current biopsy-proven malignancy
Cannot have received: neoadjuvant radiation therapy
Patients who have completed neoadjuvant chemotherapy, endocrine therapy, targeted therapy, surgical resection, or radiation for the current biopsy-proven malignancy
Cannot have received: aromatase inhibitor (anastrozole)
Patients who are planning to undergo anastrozole as standard of care neoadjuvant therapy
Cannot have received: aromatase inhibitor
Patients who are currently taking aromatase inhibitors
Cannot have received: ER antagonist (tamoxifen, raloxifene)
Patients who are currently taking ... ER antagonists (tamoxifen, raloxifene)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UW Carbone Cancer Center · Madison, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06086704 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior neoadjuvant chemotherapy, neoadjuvant endocrine therapy, neoadjuvant targeted therapy disqualifies patients from enrollment.
Does this trial require PGR?
Yes, PGR expression is a required biomarker for enrollment.
Are patients with ERBB2 alterations eligible?
No. ERBB2 overexpression is an exclusion criterion.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages